MONDAY, January 08, 2016 - TAIWAN - A new drug platform and product development biotechnology company in developing the new drug platform for potential cancer treatment and managing the oncology products at clinical stage.
EndoTAG™ technology platform is a novel, cationic liposomal technology that targets vascular endothelial cells in regenerated blood vessels which carry negative electric charges within the tumor.
SB01 is an injectable formulation of a novel heterocyclic combretastatin A-4 (CA-4) analogue drug candidate that inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin.
EndoTAG™ technology platform is a novel, cationic liposomal technology that targets vascular endothelial cells in regenerated blood vessels which carry negative electric charges within the tumor. Different from the other liposomal-embedded drug delivery systems which directly only targets the cancer cells, EndoTAG™ destroys cancerous cells through anti-angiogenesis.
EndoTAG™-1, is a synergistic product of an innovative composition of the established cytotoxic drug paclitaxel combined with EndoTAG™ technology, interacts with newly formed, negatively charged endothelial cells, which are specifically required for the growth of tumor blood vessels. It attacks the activated endothelial cells as they divide, thus EndoTAG™-1 only targets the blood supply to tumors but does not affecting healthy tissues. EndoTAG™-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.
SB01 is an injectable formulation of a novel heterocyclic combretastatin A-4 (CA-4) analogue drug candidate that inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. It mostly exhibits both tubulin binding ability and cytotoxicity. The action of tubulin binding molecules induces cell cycle arrest in the G2-M phase, forming abnormal mitotic spindles and finally leading to apoptotic cell death. SB01 has initiated Phase II clinical trial in Head and Neck Squamous Cell Carcinoma (HNSCC).